Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab
- 1 December 2001
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 68 (4), 292-294
- https://doi.org/10.1002/ajh.10043
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factorsJournal of Medical Virology, 2000
- Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximabBlood, 2000
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literatureAnnals of Hematology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatmentDigestive Diseases and Sciences, 1992